drugset / Trial / NCT02627677
A Study Comparing Ponatinib and Nilotinib in Participants With Chronic Myeloid Leukemia
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to compare the efficacy and safety of 2 starting doses of ponatinib compared to nilotinib in participants with imatinib-resistant chronic myeloid leukemia (CML) in chronic phase (CP).
Timeline
- Start
- 2015-12-31
- Primary completion
- 2020-10-29
- Completion
- 2021-01-20
Outcome
Outcome not reported
Stopped: “The study was stopped due to operational feasibility and not due to any safety concerns”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Nilotinib | Small molecule | 400 mg | Oral |
| Subject | Ponatinib | Small molecule | 15 mg | Oral |
| Subject | Ponatinib | Small molecule | 30 mg | Oral |